Revolutions Medicine, RMC-GI-102, PhI/II, GI Solid Tumors, RAS(ON)

Join this Study
What is the Purpose of this Study?

Primary Objective: (1) Safety and tolerability of interventions on each subprotocol and (2) RP2D for interventions on each subprotocol Secondary Objectives: (1) Characterization of PK and (2) antitumor activity (ORR, DOR, DCR, TTR, and PFS per RECIST 1.1)

Eligibility

  • All Patients (unless otherwise noted):
  • * ≥ 18 years of age
  • * ECOG PS is 0 to 1
Show more
Where can I participate?

CS Cancer at Cedars-Sinai Medical Center : Abrahm Levi

More about this Clinical Trial

What is the full name of this clinical trial?

RMC-GI-102: Study of RAS Inhibitors in Patients with Advanced Gastrointestinal Solid Tumors

Study Details
Disease Type/Condition

Other Digestive Organ

Principal Investigator

Osipov, Arsen

Co-Investigators

Andrew Hendifar, Emily Kaymen, Jun Gong, Kamya Sankar

Age Group

Adult

Phase

I/II

IRB Number

STUDY00004041

ClinicalTrials.gov ID

NCT06445062

Key Eligibility
ClinicalTrials.gov
How do I learn more about this study?
Name

Abrahm Levi

Email
Abrahm.Levi@cshs.org
Study Detail
Disease Type/Condition

Other Digestive Organ

Principal Investigator

Osipov, Arsen

Age Group

Adult

Phase

I/II

IRB Number

RMC-GI-102

ClinicalTrials.gov ID

NCT06445062

Key Eligibility
ClinicalTrials.gov
Contact
Name

Abrahm Levi

Email
Abrahm.Levi@cshs.org
SEND A MESSAGE
Study Details
Join this Study